Novo Nordisk A/S
BISPECIFIC ANTIBODIES
Last updated:
Abstract:
The invention relates to a bispecific antibody comprising a first antigen-binding site capable of binding Factor VII(a) and a second antigen-binding site capable of binding TLT-1, pharmaceutical formulations comprising such bispecific antibodies and uses thereof.
Status:
Application
Type:
Utility
Filling date:
21 Mar 2022
Issue date:
7 Jul 2022